co_sos
1 records
courtlistener_docket
2 records
IN RE AMGEN INC. v. AMNEAL PHARMACEUTICALS, INC.
2026-05-05
Federal docket 1:26-mc-00062 (dcd); matched party 'AMGEN INC.'
View Source
Sanjay Sharma v. Amgen Inc.
2026-04-21
Federal docket 2:26-cv-04205 (cacd); matched party 'Amgen Inc.'
View Source
Department of Justice
1 records
DOJ: Amgen to Pay U.S. $24.9 Million to Resolve
False Claims Act Allegations 2013-04-16
False Claims Act Allegations 2013-04-16
Amgen Inc., a California-based biotechnology company, has agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act, the Justice Department announced to...
View Source
epa_echo
1 records
fda
7 records
FDA Drug Recall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Onl
2025-03-26
Class II — Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
View Source
FDA Drug Recall: Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL singl
2025-03-26
Class II — Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
View Source
FDA Drug Recall: MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 10
2022-05-18
Class II — Defective container: loose crimp defect, potential loss of container integrity.
View Source
FDA Drug Recall: Procrit (epoetin alfa), 10,000 units/mL, packaged in a) box of 6 single use 1 mL
2017-09-27
Class II — Presence of particulate matter: glass flakes identified as lamellae observed during a routine quality inspection.
View Source
FDA Drug Recall: Procrit Epoetin Alfa 40,000 units/mL single use vial For Intravenouse or Subcuta
2017-08-23
Class II — Presence of particulate matter: Visible glass flakes identified as lamellae in some drug product vials.
View Source
FDA Drug Recall: AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused port
2016-12-28
Class II — Lack of Assurance of Sterility: Potential cracks in glass vials
View Source
FDA Drug Recall: Prolia (denosumab) Injection, 60 mg/mL, 1 x 60 mg Single Use Prefilled Syringe p
2013-11-13
Class II — Presence of Particulate Matter: Visible cellulose fibers were observed in a small number of prefilled syringes during a routine quality examination.
View Source
fda_adverse
2 records
ftc_enforcement
4 records
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
2023-12-14
FTC live enforcement action FY2023; matched respondent 'Amgen, Inc.'
View Source
Amgen Inc. and Horizon Therapeutics plc, FTC v.
2023-05-16
FTC live enforcement action FY2023; matched respondent 'Amgen Inc.'
View Source
Amgen Inc. and Immunex Corporation
2002-09-06
FTC live enforcement action FY2002; matched respondent 'Amgen Inc.'
View Source
Immunex Corp / Amgen Inc./AHP
2002-07-12
FTC merger enforcement action FY2002 matter 210059; matched respondent 'Amgen Inc.'
View Source
lobbying
22 records
Lobbying Client: AMGEN INC.
Lobbied by JEFFREY J. KIMBELL & ASSOCIATES, INC. — pharmaceutical
View Source
Lobbying Client: AMGEN, INC.
Lobbied by WILLIAMS AND JENSEN, PLLC — An American multinational biopharmaceutical company
View Source
Lobbying Client: AMGEN INC.
Lobbied by SONORAN POLICY GROUP, LLC D/B/A STRYK GLOBAL DIPLOMACY, FORM — Pharmaceutical manufacturer
View Source
Lobbying Client: AMGEN
Lobbied by HAGGERTY POLICY SOLUTIONS — Biopharmaceutical manufacturer
View Source
Lobbying Client: AMGEN, INC.
Lobbied by WILLIAMS AND JENSEN, PLLC — An American multinational biopharmaceutical company
View Source
Lobbying Client: AMGEN INC.
Lobbied by JEFFREY J. KIMBELL & ASSOCIATES, INC. — pharmaceutical
View Source
Lobbying Client: AMGEN, INC.
Lobbied by WILLIAMS AND JENSEN, PLLC — An American multinational biopharmaceutical company
View Source
nppes
1 records
ny_corps
1 records
NY Corp: AMGEN INC.
1989-12-28
FOREIGN BUSINESS CORPORATION | County: New York | Jurisdiction: Delaware
View Source
SEC EDGAR
1 records
sec_efts
1 records
USASpending
1 records
Federal Award: AMGEN INC. — $7,290,924
2023-08-28
NPLATE ADMINISTRATION KIT DEVELOPMENT FOR THE TREATMENT OF APPROVED INDICATIONS, INCLUDING ACUTE RADIATION SYNDROME (ARS)
View Source
Be informed when major changes happen on C.F.A.I. — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.